Bedrijfsoverzicht
Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical entity dedicated to the development of advanced cell therapies designed to treat patients suffering from autoimmune diseases. The company operates within the healthcare sector, specifically focusing on the biotechnology industry, which implies a high degree of scientific complexity and regulatory scrutiny associated with developing novel therapeutic candidates. As of the latest data, the company holds a market capitalization of $541.07M and employs 130 individuals to execute its research and development initiatives. While specific annual revenue figures are not currently disclosed in the available data, the market cap of $541.07M suggests that the market places significant value on the company's pipeline of products, particularly its lead candidate KYV-101, despite the absence of commercial revenue at this stage.
Financiële gezondheid
The company reports a net income of $-161,307,000 and an EBITDA of $-168,028,000 over the trailing twelve months, while revenue data is currently unavailable. The substantial gap between the reported net income loss and the EBITDA loss highlights the impact of significant non-operating expenses or specific accounting adjustments that widen the deficit beyond core operational cash generation. Free cash flow stands at $-92,077,504, indicating that the company is currently burning cash to fund its development activities, which limits immediate financial flexibility and necessitates reliance on external capital sources. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, a figure typical for pre-revenue biotechnology firms where revenue has not yet been recognized or is negligible relative to costs. The balance sheet shows $279.25M in cash against $29.03M in debt, resulting in a debt-to-equity ratio of 12.50, which indicates a leveraged position relative to equity but provides a substantial liquidity buffer for R&D expenditures. Furthermore, the current ratio of 7.75 suggests strong short-term liquidity, as the company holds significantly more current assets than current liabilities, ensuring it can meet its immediate obligations without distress. Return on Equity is -64.7% and Return on Assets is -35.5%, metrics that reflect the dilutive nature of losses in a growth-stage company where management is prioritizing asset accumulation and pipeline advancement over immediate shareholder returns.
Waarderingsbeoordeling
The company's valuation metrics present a challenging picture, with a Price to Book ratio of 2.33 suggesting the market prices the stock at a premium relative to its tangible book value. Trailing P/E and Forward P/E data are difficult to interpret conventionally, with the Forward P/E listed as -3.14 due to the negative earnings environment, while the trailing P/E is not applicable (N/A) given the lack of profitability. The EV/EBITDA multiple is -1.73, which, combined with the negative forward earnings, implies that traditional earnings-based valuation models are not currently relevant for assessing the company's intrinsic value. The stock's price has fluctuated significantly over the last year, ranging from a 52-week low of $1.78 to a 52-week high of $13.67. Without a specific current share price provided in the source data, the exact position relative to the range cannot be calculated, but the wide spread between the low and high indicates high volatility. The beta of 2.64 confirms that the stock price is highly sensitive to market movements, exhibiting volatility that is more than double that of the broader market.
Growth & Income
Revenue growth and earnings growth rates are both listed as N/A, reflecting the company's status as a pre-commercial entity that has not yet achieved sustained profitability or consistent revenue streams. Consequently, the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning all available capital is reinvested into research and development rather than distributed to shareholders. This reinvestment strategy is standard for clinical-stage biopharmaceuticals aiming to advance their pipeline toward market approval. The overall growth and income profile is characterized by a complete absence of current financial returns, with the business model relying entirely on future product approvals to generate the revenue necessary to support the current burn rate.